TORONTO (MedPage Today) -- Adding the fourth-generation fluoroquinolone moxifloxacin (Avelox) to standard tuberculosis therapy may allow treatment times to be shortened, an international study suggests.
aveloxNovel TB Regimen May Allow Shorter TreatmentMedPage Today Infectious Disease Thu, 04/02/2009 - 16:30
|
